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1. Introduction 
Normal isolated adrenal cells [ 1,2] are markedly 
and specifically stimulated by a singular polypeptide 
hormone, ACTH, in the production of corticosterone, 
indicating that these cells contain only one type of 
plasma membrane receptors that are coupled to the 
steroid metabolism. Adrenocortical carcinoma 494 
[3] cells [4], in contrast, possess two additional 
epinephrine-binding receptors, a-adrenergic [5] and 
P-adrenergic [63. While the biological function of 
these ectopic catecholamine-sensitive r ceptors is 
unknown, there is evidence that fl-adrenergic recep- 
tors are coupled to adenylate cyclase [7] and cu-adren- 
ergic receptors to guanylate cyclase [8]. Thus the 
model system of neoplastic adrenal cells not only 
provides the opportunity to assess the relationship of 
these epinephrine-sensitive receptors in the endocrine 
control of neoplasia, it also enables the studies 
designed to elucidate the molecular mechanism of 
their hormonal regulation and transduction of the 
biological signal. Such studies could be greatly facili- 
tated if these individual receptors could be isolated 
and purified. CHAPS, a zwitterionic detergent, has 
been originally used for the solubilization of opiate 
receptors [9]. Here, this detergent was successfully 
utilized in the selective solubilization of a-receptors. 
The results indicate that these receptors are of exclu- 
sively c+subtype. While the only biological function 
of qreceptors has been ascribed to the inhibition of 
adenylate cyclase [ lO,ll], these results together with 
[8], indicate that another major function of these 
Abbreviations: [‘HIDHE, [‘Hldihydroergocryptin; [3H]- 
DHA, [‘Hldihydroalprenolol; CHAPS, 3-[ (3cholamidopro- 
pyl)dimethylammonioj-l-propane sulfonate 
receptors may be the mediation of epinephrine- 
induced transmembrane signal via the activation of 
guanylate cyclase. Such a hormonal pathway would 
rationalize the mediatory role of cyclic GMP in the 
transduction of membrane signal. 
2. Materials and methods 
Adrenocortical carcinoma 494, a spontaneously 
occurring tumor discovered in [3] and maintained in 
our laboratory [4] was used for the membrane prepa- 
ration and binding studies. 
[3H]DHE (spec. act. 39.9 Ci/mmol), and 13H]- 
DHA (spec. act. 43.0 Ci/mmol) and 12’I-ACTH (spec. 
act. 30 /.&i/pg) were obtained from New England 
Nuclear; (-)-epinephrine bitartrate, (-)-norepineph- 
rine hydrochloride, yohimbine hydrochloride, ergot- 
amine tartrate, ar-ergocryptine, (-)-isoproterenol 
‘hydrochloride, and (+)-propranolol hydrochloride 
were from Sigma. ACTH1_39 was from USP Cortico- 
tropln Reference Standard (Bethesda MA); phentol- 
amine hydrochloride, prazosin hydrochloride and 
QUSO G-32 were gifts from Ciba-Geigy, Pfizer Inc. 
and Philadelphia Quartz Co., respectively. PD-10 Col- 
umns were purchased from Pharmacia Fine Chemicals. 
2.1. Membrane preparation 
Adrenocortical carcinoma membranes were pre- 
pared as in [ 121 with minor modifications. The fresh 
tumor tissue was collected into 10 mM Tris (pH 7.5) 
maintained on ice. Necrotic cells were removed, sur- 
rounding fibrous tissues were dissected away, and 
viable tissue was homogenized in 6 vol. ice cold 
buffer (0.25 M sucrose, 1 mM MgC12, 5 mM Tris-HCl 
(pH 7.5) for 4 X 30 s periods in a Brinkman Polytron 
98 
hblished by Elsevier Biomedical R-ess 
00145793/82/0000-0000/$02.75 0 1982 Federation of European Biochemical Societies 
Volume 140, number 1 FEBS LETTERS April 1982 
at a setting of 6. After filtration through a double 
layer of gauze, the homogenate was centrifuged at 
400 X g for 10 min at 4°C and the supernatant 
recentrifuged at 28 000 X g for 10 mm at 4°C. The 
resulting pellet was washed twice in ice cold incuba- 
tion buffer (10 mM MgC12, 50 mM Tris-HCl (pH 7.5)) 
by resuspension and centrifugation at 28 000 X g for 
10 min. The final pellet resuspended in incubation 
buffer was used for the binding assays. Protein was 
determined by the Bradford method using bovine 
serum albumin as a standard [ 131. 
2.2. Solubilization of receptors 
Adrenocortical carcinoma membranes were solubil- 
ized as in [9]. To the membrane suspension (~4 mg/ 
ml) was added 50 pg/ml lima bean trypsin inhibitor, 
0.01% dimethyl sulfoxide and 10 mM CHAPS (final 
cont.). This was stirred vigorously on ice for 1 h, then 
centrifuged at 105 000 X g for 60 min. The clear, 
slightly yellow supernatant was used for the binding 
studies. 
2.3 . Binding assays 
2.3.1. Membranes 
The binding assays were performed as indicated 
below unless otherwise stated. [ 3H] DHE (8 nM) and 
adrenocortical carcinoma membranes (-400 pg/assay) 
were incubated at 37’C for 20 min in a total volume 
of 1 .O ml incubation buffer (10 mM MgCl?, 50 mM 
Tris-HCl (pH 7.5)). Incubation was terminated by 
diluting the incubation mixture with 5 ml buffer fol- 
lowed by immediate filtration through Whatman 
GF/A glass fiber filters which were washed with 
4 X 5 ml incubation buffer. This procedure signifi- 
cantly reduced the non-specific binding of the ligand. 
After drying, filters were counted for radioactivity in 
Omniflor/toluene scintillation mixture. Non-specific 
binding was measured in the presence of 0.1 mM 
phentolamine, a potent cw-adrenergic antagonist. 
2.3.2. Solubilized fractions 
Aliquots of the solubilized receptors were incu- 
bated in 1 .O ml final vol. for 20 min at 37’C in a mix- 
ture containing 50 mM Tris, 10 mM MgC12 (pH 7.5) 
and 8 nM [3H] DHE. The reaction was stopped by 
adding 1.5 ml 10 mM Tris and 0.32 M sucrose 
(pH 7.5). After cooling on ice, the mixture was applied 
to a Sephadex G-25 column (PD-lo), pre-equilibrated 
with 0.32 M sucrose, 10 mM Tris-HCl (pH 7.5). The 
initial 2.5 ml effluent was discarded. The high Mr 
fraction, eluted in the next 3.5 ml was collected and 
counted for radioactivity with 12 ml Scintiverse. 
Non-specifically bound radioactivity was determined 
in the presence of 0.1 mM phentolamine in the incu- 
bation mixture. All the experiments were done in 
triplicate and repeated at least 2 times. The specific 
binding was between 15-30% of the total counts 
bound. 
3. Results 
The zwitterionic detergent CHAPS is very selective 
in solubilizing a-adrenergic receptors. Adrenocortical 
carcinoma tissue contains CK- and P-adrenergic as well as 
ACTH receptors. When binding studies were done for 
all the 3 receptors, it was found that only cr-adrener- 
gic receptors were solubilized (table 1). The recovery 
of protein in the solubihzed fraction was w-30-45% 
with the specific activity of [‘HI DHE binding almost 
the same as that for the membrane receptors. The 
solubilized receptors exhibited identical binding char- 
acteristics as the membrane receptors. Fig.lA shows 
the binding of various concentrations of [3H] DHE to 
the solubilized receptors. The saturation curve revealed 
Table 1 
Presence of adrenergic and ACTH receptors in adrenocortical 
carcinoma particulate and solubilized fractions 
Particulate Solubilized 
(fmol/mg protein) 
or-Adrenergic receptors 
[ SH]DHE binding 50.1 + 1.2 62.8 + 1.9 
fi-Adrenergic receptors 
[ ‘HIDHA binding 29.1 f 3.0 Non-detectable 
ACTH receptors 
‘WACTH binding 43.0 f 3.2 Non-detectable 
a- and fl-Adrenergic receptors were quantitated both in the 
membrane and solubilized fractions as in section 2. The pro- 
cedure for p-adrenergic receptor binding was the same as that 
of a-adrenergic receptors except the radioligand used was 
isH]DHA and non-specific binding was measured in the pres- 
ence of 0.1 mM isoproterenol. ACTH binding was done on 
ice for 10 min using “%ACTH and nonspecific binding was 
measured in the presence of lOOO-fold excess of ACTH, _-39. 
The total assay volume was 0.5 ml and the reaction was 
stopped by diluting the reaction mixture to 1.5 ml with incu- 
bation buffer (50 mM Tris-HCI (pH 7.5)). To this was added 
10 mg QUSO and let stand for 10 mln on ice. The bound 
“SI-ACTH was separated from the free by centrifugation and 
the supernatant was counted for radioactivity in a y-counter 
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Fig.1. (A) Specific binding of [ sH]DHE to solubilized recep- 
tors as a function of [sH]DHE concentration. The solubilized 
receptors were incubated at 37°C for 20 min with various 
concentrations of [ 3H]DHE and the reaction was stopped by 
diluting the incubation mixture with buffer (10 mM Tris, 
0.32 M sucrose (pH 7.5)) and passing through a PD-10 col- 
umn; 3.5 ml column effluent was collected and counted for 
radioactivity after discarding the initial 2.5 ml. Non-specific 
binding was measured in the presence of 0.1 mM phentol- 
amine-HCl. Experiments were repeated at least 3 times in 
triplicate and the results are representative of 1 expt. (B) 
[‘HIDHE binding at 37°C and 23’C with solubilized recep- 
tors as a function of time. Incubations were done for various 
time intervals at 37°C and 23°C and processed as mentioned 
in’(A). Concentration of [‘HIDHE was 8 nM. 
a Kd of -4 nM and maximum binding of 3 5 fmol/mg 
protein. The binding of [3H]DHE at 37’C and 23’C 
for various time intervals is shown in fig.lB. The bind- 
ing is rapid reaching maximum in 20 min at 37’C and 
in 10 mm at 23’C. The potency of various adrenergic 
ligands to displace [3H]DHE binding in membranes 
was retained in the solubilized fraction. Fig.2 shows 
the displacement of [3H] DHE binding from the 
receptor by various adrenergic agonists and antagonists. 
Half-maximal inhibition of [3H]DHE binding was 
exhibited at 1 X 10V6 M, 8 X lo-’ M and 2 X lo4 M 
for epinephrine, norepinephrine and isoproterenol, 
respectively. Among the antagonists yohimbine was 
potent in displacing the bound [ 3H] DHE. Prazosin 
(cur-antagonist) was without any effect on the displace- 
ment of [3H] DHE from the binding sites. In addition, 
the membrane receptors bound [3H]yohimbine 
which can be displaced >90% by non-radioactive 
yohimbme and 65--70% by phentolamine and epi- 
nephrine (not shown). This confirms [ 141 the obser- 
vation made in the adrenocortical carcinoma mem- 
branes that these cu-adrenergic receptors belong to 
ar,subclassification. Propranolol @-antagonist) did 
not have any effect on [3H] DHE binding. 
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Fig.2. Displacement of bound [3H]DHE from solubilized 
receptors by various agonists (top) and antagonists (bottom). 
Specific binding of [‘H ] DHE was measured in the presence 
and absence of different concentrations of various agonists 
and antagonists. Assay conditions are the same as mentioned 
in fig.lA. Concentration of [=‘H]DHE was 8 nM. Top: (0) 
epinephrine, (m) norepinephrine, (A) isoproterenol. Bottom: 
(0) yohimbine, (A) prazosin-HCl, (0) propranolol-HCl. 
4. Discussion 
The native adrenocortical carcinoma cell mem- 
branes contain ACTH-, o-adrenergic and P-adrenergic 
receptors [5,6,15]. The treatment of the crude mem- 
branes with CHAPS selectively solubilizes receptors 
having characteristics of true o-adrenergic receptors. 
These bind [ 3H] DHE rapidly with a high affinity (Kd 
4 X lO+ M), in a saturable fashion (35 fmol/mg pro- 
tein) and the potency of o-agonists and antagonists to 
displace [3H]DHE is higher than that of fl-adrenergic 
agonists and antagonists. 
That the cY-adrenergic binding activity is indeed 
soluble was established, since it neither sediments at 
105 000 X g for 1 h nor does it show any membrane 
characteristics upon electron microscopic examina- 
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tion (not shown). Since the presence of ACTH- or 
/3-adrenergic receptors was not detected in the solubil- 
ized preparation, these studies demonstrate hat the 
adrenocortical carcinoma cw-adrenergic re eptors are 
not only solubilized by the CHAPS treatment, but 
they also retain the original a-adrenergic characteris- 
tics of the native membranes. 
Based on the binding studies of receptors with spe- 
cific radioactive ligands, in many tissues the ar-adren- 
ergic receptors have been classified into o1 and o2 
subtypes [16-l 81. cr2-Adrenergic receptors how 
higher affinity for yohimbine and little affinity for 
q-antagonist prazosin and WB-4101. However, the 
reverse is the case for cq-adrenergic receptors. Based 
on these criteria the solubilized adrenocortical carci- 
noma membranes are exclusively of cw2-subtype, since 
they have a high affinity for yohimbine (ECse lo-’ M) 
and no affinity for prazosin. It is generally believed 
that cu2-receptors p edominantly reside on presynap- 
tic sites on the nerve terminals and their function is 
the inhibition of norepinephrine r lease by feedback 
mechanism [ 17,191. However, these receptors coexist 
with cri-receptors in rat heart membranes [20], rat 
brain [21] and hamster adipocytes [22], and predomi- 
nantly [23] or exclusively in human platelets [24-271. 
During the course of this investigation, solubiliza- 
tion of the human platelet as-adrenergic receptors by 
digitonin treatment *was reported 125,271. There is, 
however, one important difference between the charac- 
teristics of the solubilized receptors of platelets and 
adrenocortical carcinoma membranes. The solubilized 
platelet receptors how a reduced affinity for agonists 
as compared to the native receptors [25,27]; in con- 
trast, the ar2-agonist and antagonist affinity for the 
native and solubilized carcinoma membrane receptors 
remains unchanged. Such a difference between the 
native and solubilized platelet cY,receptor has led to 
the interpretation that the digitonin treatment results 
in the loss of a receptor component protein that is 
essential for the interaction of the a2-receptor with 
the GTP-binding protein [25,27]. Such an interpreta- 
tion is obviously not necessary in the case of the solu- 
bilized adrenocortical carcinoma membrane receptors 
prepared by the CHAPS treatment. 
The molecular mechanism by which qadrenergic 
receptors exhibit their biological activity is not 
known. Since these receptors in many tissues exam- 
ined inhibit adenylate cyclase [lo,1 11, it has been 
proposed that crs-receptors are coupled to the adenyl- 
ate cyclase in an inhibitory manner. In such a hypo- 
thesis, both the @-adrenergic and cu*adrenergic agonists 
will exhibit their biological activity by interacting with 
the adenylate cyclase, the /I-adrenergic agonist stimu- 
lating it and the cuZ-adrenergic agonist inhibiting it. 
The results with intact isolated adrenocortical car- 
cinoma cells indicate that the epinephrineactivated rise 
of cyclic GMP is mediated by the a-adrenergic receptors 
[8]. The demonstration that these o-receptors are 
exclusively of the cY2-subtype in native membranes 
indicates that the epinephrine-activated rise of cyclic 
GMP in intact cells is mediated by the curadrenergic 
receptors. This then indicates that the aa-adrenergic 
receptors are coupled to guanylate cyclase and the 
transmembrane signal induced by the a2-agonist 
occurs by its interaction with the a2-adrenergic recep- 
tors which in turn results in the rise of cyclic GMP. 
All these results indicate that the cw2-adrenergic 
coupled guanylate cyclase system might be one of the 
means of transmitting the catecholamine-sensitive b o- 
logical response in the adrenocortical carcinoma cell. 
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